Home » Stocks » AVRO

Avrobio, Inc. (AVRO)

Stock Price: $14.59 USD 0.55 (3.92%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
Market Cap 604.77M
Revenue (ttm) n/a
Net Income (ttm) -114.24M
Shares Out 36.44M
EPS (ttm) -3.31
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $14.59
Previous Close $14.04
Change ($) 0.55
Change (%) 3.92%
Day's Open 14.06
Day's Range 13.55 - 14.64
Day's Volume 335,682
52-Week Range 10.08 - 27.21

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 1 day ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today ...

Business Wire - 4 days ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today...

Business Wire - 2 weeks ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today...

Business Wire - 2 weeks ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today...

Seeking Alpha - 4 weeks ago

AVROBIO, Inc. is a clinical-stage gene therapy biotechnology company focused on developing single-dose curative ex-vivo lentiviral-based gene therapies for rare diseases. AVROBIO is developing...

Seeking Alpha - 4 weeks ago

AVROBIO is developing gene therapies for lysosomal disorders where lifelong enzyme replacement therapy is the SoC. Early stage data shows promise.

Business Wire - 1 month ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today...

Business Wire - 1 month ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced the closing of its previously announced underwritten p...

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced the pricing of an underwritten public offering of 5,00...

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company, today announced that it intends to offer and sell, subject to market an...

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today...

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today...

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today...

Zacks Investment Research - 2 months ago

Let us take a look at some drug/biotech stocks that are poised to beat on third-quarter earnings.

Other stocks mentioned: ACAD, ALNY, BHVN, BNTX
Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today...

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today...

Business Wire - 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today...

Business Wire - 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today...

Zacks Investment Research - 3 months ago

AVROBIO's (AVRO) gene therapy candidate for Gaucher disease, AVR-RD-02, gets orphan drug designation from the European Commission.

Business Wire - 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today...

Business Wire - 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today...

Business Wire - 4 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc.

Business Wire - 4 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc.

Zacks Investment Research - 5 months ago

Let us take a look at some biotech stocks that are poised to beat on second-quarter earnings.

Other stocks mentioned: ARCT, ETNB, FULC, ICPT
Business Wire - 5 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc.

Business Wire - 5 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc.

Zacks Investment Research - 5 months ago

AVROBIO has been struggling lately, but the selling pressure may be coming to an end soon

Business Wire - 6 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today...

Business Wire - 6 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today...

Zacks Investment Research - 8 months ago

AVROBIO (AVRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Investment Research - 9 months ago

AVROBIO (AVRO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

24/7 Wall Street - 9 months ago

The COVID-19 pandemic has changed normal operations for companies across the world as they cope with resource limitations, health precautions and other challenges.

Other stocks mentioned: FATE, KNSA, MRSN, NVCR, ORTX, SYBX, TCRR
Zacks Investment Research - 10 months ago

AVROBIO, Inc. (AVRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

The Motley Fool - 11 months ago

The small-cap biopharmaceutical company announced a public stock offering.

Seeking Alpha - 1 year ago

AVROBIO: Promise In Fabry Disease

Zacks Investment Research - 1 year ago

AVROBIO, Inc. (AVRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research - 1 year ago

AVROBIO, Inc. (AVRO) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Seeking Alpha - 1 year ago

The company recently reported impressive data for its gene therapy in Fabry's disease.

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor AVROBIO.

The Motley Fool - 1 year ago

Despite declines in the broader market, good news lifted shares of these companies.

Other stocks mentioned: AG, SGEN
24/7 Wall Street - 1 year ago

AvroBio Inc. (NASDAQ: AVRO) shares continued their run on Wednesday, despite the firm announcing that it would conduct a secondary offering.

The Motley Fool - 1 year ago

The gene therapy developer announced higher-than-expected demand for its public stock offering.

24/7 Wall Street - 1 year ago

Tuesday was a breakout day for a few biotech companies that saw solid gains. With the markets at all-time highs, these companies could help push things higher.

Other stocks mentioned: ATRA, MLNT

About AVRO

AVROBIO, a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease. The company's lead product candidate is AVR-RD-01, which is in ongoing Phase II clinical trial and investigator-sponsored Phase I clinical trial for the treatment of ... [Read more...]

Industry
Biotechnology
IPO Date
Jun 21, 2018
CEO
Geoff MacKay
Employees
123
Stock Exchange
NASDAQ
Ticker Symbol
AVRO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for Avrobio stock is "Strong Buy." The 12-month stock price forecast is 36.71, which is an increase of 151.61% from the latest price.

Price Target
$36.71
(151.61% upside)
Analyst Consensus: Strong Buy